Jeffrey Weber, MD, PhD: The Impact of BRAF/MEK Inhibitors in Melanoma - ViDoe

Jeffrey Weber, MD, PhD: The Impact of BRAF/MEK Inhibitors in Melanoma

153 views

Targeted Oncology

8 years ago

Jeffrey Weber, MD, PhD: The Impact of BRAF/MEK Inhibitors in Melanoma

Jeffrey Weber, MD, PhD: The Impact of BRAF/MEK Inhibitors in Melanoma

$Jeffrey Weber, MD, PhD: The Impact of BRAF\/MEK Inhibitors in Melanoma$

1:28

Jeffrey Weber, MD, PhD: The Impact of BRAF\/MEK Inhibitors in Melanoma

by Targeted Oncology

$Melanoma: BRAF\/MEK-Inhibitors as Adjuvant Therapy$

7:23

Melanoma: BRAF\/MEK-Inhibitors as Adjuvant Therapy

Jeffrey Weber, MD, PhD explains the long term data from Keynote-001 study in advanced melanoma

2:26

Jeffrey Weber, MD, PhD explains the long term data from Keynote-001 study in advanced melanoma

Jeffrey Weber, MD, PhD, discusses the efficacy of checkpoint inhibitors and immunotherapy

1:54

Jeffrey Weber, MD, PhD, discusses the efficacy of checkpoint inhibitors and immunotherapy

Jeffrey Weber, MD, PhD explains the importance of testing for NRAS as compared with a BRAF Biomarker

1:46

Jeffrey Weber, MD, PhD explains the importance of testing for NRAS as compared with a BRAF Biomarker

Jeffrey Weber, MD, PhD explains the importance of administering ipilimumab with a PD-L1 inhibitor

2:34

Jeffrey Weber, MD, PhD explains the importance of administering ipilimumab with a PD-L1 inhibitor

Jeffrey Weber, MD, PhD provides interpretation of the NEMO trial results

1:26

Jeffrey Weber, MD, PhD provides interpretation of the NEMO trial results

Jeffrey Weber, MD, PhD discusses the long term side effects with immunotherapies

1:23

Jeffrey Weber, MD, PhD discusses the long term side effects with immunotherapies

Dr. Weber on the Future of Checkpoint Inhibitors in Melanoma

1:05

Dr. Weber on the Future of Checkpoint Inhibitors in Melanoma

Dr. Weber on Emerging Therapies in Melanoma

0:49

Dr. Weber on Emerging Therapies in Melanoma

$Dr. Weber on Side Effects of Dabrafenib\/Trametinib in Melanoma$

1:27

Dr. Weber on Side Effects of Dabrafenib\/Trametinib in Melanoma

2022 IME Dr. Jeffrey S. Weber, MD, PhD invites you to the 18th Annual IME Conference on Melanoma

0:42

2022 IME Dr. Jeffrey S. Weber, MD, PhD invites you to the 18th Annual IME Conference on Melanoma

by Physicians' Education Resource

Dr. Jeffrey Weber on CheckMate-064 Trial for Advanced Melanoma

2:18

Dr. Jeffrey Weber on CheckMate-064 Trial for Advanced Melanoma

$Dr. Jeffrey Weber on Potential Breakthrough \\$

1:21

Dr. Jeffrey Weber on Potential Breakthrough \\"Cures\\" in Melanoma

by Targeted Oncology

Dr. Weber on CheckMate-238 Compared to Other Trials in Melanoma

1:17

Dr. Weber on CheckMate-238 Compared to Other Trials in Melanoma

Tocilizumab with ipilimumab and nivolumab in unresectable melanoma

1:00

Tocilizumab with ipilimumab and nivolumab in unresectable melanoma

$Dr. Weber on Dabrafenib\/Trametinib Approval for Melanoma$

1:46

Dr. Weber on Dabrafenib\/Trametinib Approval for Melanoma

Dr. Weber on Risk and Benefits With Immunotherapy Combos in Melanoma

1:03

Dr. Weber on Risk and Benefits With Immunotherapy Combos in Melanoma

Jeffrey Weber, MD, PhD: Factors to Consider When Determining Treatments

1:28

Jeffrey Weber, MD, PhD: Factors to Consider When Determining Treatments

by Targeted Oncology

Clinical trials investigating the treatment of melanoma

1:13

Clinical trials investigating the treatment of melanoma